Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
- Conditions
- AmyloidosisLight Chain Deposition Disease (LCDD or MIDD)Monoclonal Immunoglobulin Deposition Disease (MIDD)Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
- Interventions
- Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01383759
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01379287
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
- Conditions
- Mesothelioma
- Interventions
- Behavioral: Questionnaires & online virtual support group
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT01356251
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery
- Conditions
- Head and Neck Cancer
- Interventions
- Other: electrocautery resection and quality of life formsOther: Flexible Fiber-based CO2 Laser, Quality of Life forms
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT01355926
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Other: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01354951
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸North Shore LIJ, New Hyde Park, New York, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT01351623
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
- Conditions
- Lung Cancer
- Interventions
- Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01349647
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT01345175
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
Telemedicine Evaluation for Stem Cell Transplant Patients
- Conditions
- Stem Cell Transplant Patients
- Interventions
- Behavioral: virtual medical visit
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01324427
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
- Conditions
- Melanoma
- Interventions
- Drug: Ipilimumab, Melphalan and Dactinomycin
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01323517
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States